Last reviewed · How we verify
Gatifloxacin combined regimen
Gatifloxacin combined regimen is a Fluoroquinolone antibiotic Small molecule drug developed by Institut de Recherche pour le Developpement. It is currently in Phase 3 development for Bacterial infections (likely respiratory, urinary tract, or other systemic infections in a combined regimen context).
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Bacterial infections (likely respiratory, urinary tract, or other systemic infections in a combined regimen context).
At a glance
| Generic name | Gatifloxacin combined regimen |
|---|---|
| Sponsor | Institut de Recherche pour le Developpement |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a fourth-generation fluoroquinolone, gatifloxacin binds to and inhibits bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This dual inhibition leads to rapid bactericidal activity. When used in a combined regimen, gatifloxacin is typically paired with other antimicrobial agents to broaden spectrum coverage and reduce resistance development.
Approved indications
- Bacterial infections (likely respiratory, urinary tract, or other systemic infections in a combined regimen context)
Common side effects
- Tendinopathy/tendon rupture
- QT prolongation
- Peripheral neuropathy
- Gastrointestinal disturbances
- Photosensitivity
Key clinical trials
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gatifloxacin combined regimen CI brief — competitive landscape report
- Gatifloxacin combined regimen updates RSS · CI watch RSS
- Institut de Recherche pour le Developpement portfolio CI
Frequently asked questions about Gatifloxacin combined regimen
What is Gatifloxacin combined regimen?
How does Gatifloxacin combined regimen work?
What is Gatifloxacin combined regimen used for?
Who makes Gatifloxacin combined regimen?
What drug class is Gatifloxacin combined regimen in?
What development phase is Gatifloxacin combined regimen in?
What are the side effects of Gatifloxacin combined regimen?
What does Gatifloxacin combined regimen target?
Related
- Drug class: All Fluoroquinolone antibiotic drugs
- Target: All drugs targeting Bacterial DNA gyrase and topoisomerase IV
- Manufacturer: Institut de Recherche pour le Developpement — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections (likely respiratory, urinary tract, or other systemic infections in a combined regimen context)
- Compare: Gatifloxacin combined regimen vs similar drugs
- Pricing: Gatifloxacin combined regimen cost, discount & access